Indian pharmaceutical firms are expanding their product pipeline in the US generics market, with multiple ANDA approvals and specialty filings underway. Companies are increasingly targeting complex generics and niche therapies to improve profitability.
Despite pipeline progress, pricing pressure in the US market continues to weigh on realisations, particularly in the base generics portfolio. Firms are responding through cost optimisation and portfolio diversification.
Analysts maintain that companies with strong compliance track records and differentiated product mix are likely to outperform over the medium term.
